198 related articles for article (PubMed ID: 34682825)
1. Progression of Fibrinogen Decrease during High Dose Tigecycline Therapy in Critically Ill Patients: A Retrospective Analysis.
Treml B; Rajsic S; Hell T; Fries D; Bachler M
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682825
[TBL] [Abstract][Full Text] [Related]
2. Tigecycline-associated hypofibrinogenemia in a real-world setting.
Campany-Herrero D; Larrosa-Garcia M; Lalueza-Broto P; Rivera-Sánchez L; Espinosa-Pereiro J; Mestre-Torres J; Pigrau-Serrallach C
Int J Clin Pharm; 2020 Aug; 42(4):1184-1189. PubMed ID: 32504166
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline Interferes with Fibrinogen Polymerization Independent of Peripheral Interactions with the Coagulation System.
Brandtner A; Bachler M; Fries D; Hermann M; Ruehlicke J; Fux V; Griesmacher A; Niederwanger C; Hell T; Treml B
Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32074981
[TBL] [Abstract][Full Text] [Related]
4. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.
Fan Q; Huang W; Weng Y; Xie X; Shi Z
Medicine (Baltimore); 2020 Oct; 99(43):e22638. PubMed ID: 33120753
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
6. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia.
Wu X; Zhao P; Dong L; Zhang X
Medicine (Baltimore); 2017 Dec; 96(49):e9124. PubMed ID: 29245350
[TBL] [Abstract][Full Text] [Related]
7. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China.
Leng B; Shen C; Gao T; Zhao K; Zhao X; Guo Y; Wu J; Yang J; Fang W; Zhang J; Zhang Y; Sun C; Duan L; Huang J; Qi Y; Yan G
Front Pharmacol; 2022; 13():943674. PubMed ID: 36304151
[No Abstract] [Full Text] [Related]
8. Tigecycline-associated hypofibrinogenemia: A case report and review of the literature.
Wu PC; Wu CC
IDCases; 2018; 11():56-57. PubMed ID: 29560313
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Hu J; Xiao YH; Zheng Y; Lai YX; Fang XL; Fang Q
Eur J Clin Pharmacol; 2020 Jul; 76(7):913-922. PubMed ID: 32355990
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Tigecycline-Associated Hypofibrinogenemia.
Liu J; Yan Y; Zhang F
Ther Clin Risk Manag; 2021; 17():325-332. PubMed ID: 33888987
[TBL] [Abstract][Full Text] [Related]
11. Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study.
Lin C; Tan M; Wang D; Gu C; Wu Y; Wang S
Pharmacology; 2023; 108(6):540-549. PubMed ID: 37751720
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study.
Firat O; Kara E; Malkan ÜY; Demirkan K; Inkaya AÇ
Thromb Res; 2024 Apr; 236():155-160. PubMed ID: 38452447
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline-induced life-threatening coagulopathy in a patient with a Mycobacterium abscess: a case report and step-by-step diagnostic approach.
Akalay S; Vanassche T; De Munter P
Acta Clin Belg; 2021 Oct; 76(5):410-414. PubMed ID: 32255411
[TBL] [Abstract][Full Text] [Related]
14. Tigecycline-induced coagulopathy: a literature review.
Cui N; Cai H; Li Z; Lu Y; Wang G; Lu A
Int J Clin Pharm; 2019 Dec; 41(6):1408-1413. PubMed ID: 31713108
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia.
Lei H; Liu X; Li Z; Wang C
J Chemother; 2023 Jul; 35(4):292-297. PubMed ID: 35904191
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous Knee Hemarthrosis Due to Hypofibrinogenemia Following Tigecycline Treatment for Periprosthetic Joint Infection.
Balfousias T; Apostolopoulos AP; Angelis S; Maris S; Papanikolaou A
Cureus; 2019 Oct; 11(10):e5883. PubMed ID: 31772853
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of tigecycline-associated fibrinogen reduction in patients with renal transplantation: a case-control study.
Xie W; Ma K; Xu Z; Xie J; Lu X; Wang X
Transl Androl Urol; 2022 Oct; 11(10):1410-1418. PubMed ID: 36386261
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline treatment causes a decrease in fibrinogen levels.
Zhang Q; Zhou S; Zhou J
Antimicrob Agents Chemother; 2015 Mar; 59(3):1650-5. PubMed ID: 25547356
[TBL] [Abstract][Full Text] [Related]
20. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.
Maseda E; Denis SE; Riquelme A; Gilsanz F
Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
